retatrutide what is retatrutide clinical trial Retatrutide: The Triple Agonist That Could Redefine Metabolic Medicine (a full breakdown from a clinical VisualAbstract: Retatrutide reduces body weight

As such, GLP-1 has been studied as a potential therapeutic for the treatment and management of high-impact neurodegenerative disorders, namely Alzheimers disease (AD) and Parkinsons disease (PD)

10.1016/S0021-9258(19)50881-X 32

As other Phase I studies using D+Q in the context of AD report out, we will be positioned to begin determining whether there is a convergence of data for specific disease states (e.g., NCT04785300 and NCT05422885 are both AD Phase I trials using D+Q), or study/site-specific changes are noted

When Se deficiency occurs in the context of already existing hypothyroidism, the symptoms of myxedema (such as puffiness of the skin, a hoarse voice, and slowness of mental function) may become more pronounced [73]